Researchers at Massachusetts General Hospital developed PET/CT imaging to assess carotid plaque inflammation, identifying patients at high risk for heart attacks. This breakthrough may lead to more targeted interventions and improved patient outcomes.
Researchers have introduced a new technique combining SPECT and spiral CT for improved bone scanning, shortening diagnostic time and clarifying findings. The technology has been shown to enhance the specificity of bone scintigraphy and reduce CT radiation exposure.
Researchers have developed a new treatment option that breaks Leukemia's resistance to chemotherapy and radiation therapy by targeting specific cells with alpha particles. This approach increases the dose to leukemia cells, causing cell kill while sparing non-target tissues from detrimental radiation effects.
Walter Wolf, distinguished professor of pharmaceutical sciences at USC, received the award for his groundbreaking work in pharmacokinetic imaging and radiopharmaceuticals. His research focuses on noninvasive studies of drug biodistribution and targeting using nuclear medicine imaging and magnetic resonance spectroscopy.
Researchers have developed a non-invasive method to detect atherosclerosis by measuring coronary blood flow, allowing for early detection and treatment of high-risk patients. The study found that elevated levels of interleukin-6 are a major determinant of coronary endothelial dysfunction in individuals with hypertension.
Gambhir, a renowned Stanford University scientist, is recognized for his extensive work in molecular imaging and basic science of using radioactive tracers. He has developed numerous methods for imaging gene/cell therapy and protein-protein interactions in living subjects.
A new time-of-flight PET scanner with LYSO detector crystals improves diagnostic accuracy and reduces variability in patient images. This technology enables more accurate detection of small lesions and better lesion characterization, leading to improved cancer diagnosis and treatment.
The Society of Nuclear Medicine and Molecular Imaging (SNM) has released a landmark procedure guideline for tumor imaging with 18F-FDG PET/CT. The document provides recommendations for patient preparation, image acquisition, interpretation criteria, and quality control to ensure high-quality imaging results.
Researchers discovered that bone marrow stromal cells can improve brain receptor function in patients with cerebral stroke, showing potential for neural tissue regeneration. The study may provide a 'missing link' needed in understanding receptor function, possibly leading to safe and ethical cell transplantation therapy.
A study in the Journal of Nuclear Medicine Technology found that physical activity, even minor exercises like turning a page or shoveling snow, can impact PET scan results and lead to false positives. To minimize this effect, patients should avoid excessive muscle activity 48 hours before scanning and inform their technologist.
The Society of Nuclear Medicine and Molecular Imaging (SNM) has awarded $30,000 in grants to three institutions in China and India. The SNM/GE Healthcare Visiting Physician/Scientist Program Grant will cover travel and per diem costs for a one- or two-week visit to lecture, train, and consult on molecular and nuclear imaging.
Researchers used PET and MR imaging to show white matter volume loss precedes clinical symptoms of Huntington's disease. The study suggests a new approach to preventing the disease at an early stage by monitoring brain tissue volumes and basal ganglia dysfunction.
The Society of Nuclear Medicine and Molecular Imaging (SNM) has awarded a $25,000 grant to aid in the development of new pilot projects focused on molecular imaging and nuclear medicine for cancer diagnosis and treatment response. The grant will support research led by Dr. Yu at the University of Tennessee Health Science Center.
The Society of Nuclear Medicine and Molecular Imaging (SNM) has awarded $75,000 in grants to support innovative pilot projects in molecular imaging/nuclear medicine research. The grants will fund research projects focused on cancer diagnosis and treatment response, including the use of existing radiotracers for new applications.
Belgian and Italian researchers developed a new imaging technique that can predict breast cancer patients' response to hormonal treatment with high accuracy. The technique uses 99mTc-depreotide scintigraphy to assess hormone sensitivity in tumors, allowing for early selection of patients likely to benefit from hormonal therapy.
Researchers used molecular imaging to detect atherosclerotic plaques likely to rupture in experimental rabbit models. The study found that dietary modification and statin therapy can decrease apoptosis and stabilize plaques, supporting the paradigm of prevention over treatment for coronary artery disease.
PET imaging with FDG is a powerful tool in determining the extent of spread of reproductive system cancers, particularly when other conventional tests are ambiguous. Studies have shown its high sensitivity in detecting nodal disease in cervical cancer and its superior detection abilities compared to CT or MRI in recurrent ovarian cancer.
A study published in Journal of Nuclear Medicine found that PET imaging with FDG has significantly higher accuracy than genetic screening for predicting Alzheimer's disease in mild cognitive impairment (MCI) patients. Most MCI patients who showed abnormalities in their original PET scan developed dementia within 16 months.
The SNM/GE Healthcare Visiting Physician/Scientist Program Grant will provide educational enrichment in China and India through one- to two-week visits. Clinical centers, hospitals, academic institutions can apply for funding to support nuclear medicine/molecular imaging training and consulting.
Researchers used PET scanning to track monoamine oxidase (MAO A) levels in smokers and nonsmokers, finding that MAO A was 50% lower in smokers' lungs. Smokers also held onto a tracer chemical longer and had reduced delivery of tracer into arterial blood supply.
Researchers found lower mu-opioid receptor binding in the left insular cortex of women with bulimia, inversely correlated with fasting behavior. This study suggests that medications targeting brain opioid receptors may help treat bulimia, a serious eating disorder marked by destructive patterns of dieting and vomiting.
A new study suggests that PET imaging can identify which breast cancer patients are likely to respond to chemotherapy, allowing for more effective treatment and improved patient outcomes. This breakthrough could lead to the development of personalized treatment plans, giving patients and doctors more options.
Researchers at Stanford University have developed a novel 3D rendering technique for PET/CT images, allowing for simultaneous viewing of multiple modalities. This new paradigm has the potential to revolutionize diagnostic and treatment procedures for various diseases.
Jan Winn, associate professor at the University of Oklahoma Health Sciences Center, has been honored with the Outstanding Educator Award by the Society of Nuclear Medicine Technologist Section. She is praised for her ability to explain complex concepts and incorporate new information into her classes.
Michael R. Zalutsky, a professor at Duke University Medical Center, has been honored with the 2005 Berson-Yalow Award for his pioneering work in targeted radiotherapy. His research focuses on developing molecularly targeted radiodiagnostics and radiotherapeutics for oncologic applications.
A recent UCLA study has found a significant association between obesity and impaired coronary circulatory function, highlighting the importance of early detection and monitoring. Quantitative PET imaging may help identify at-risk individuals, enabling targeted interventions to prevent cardiovascular events.
Researchers used SPECT imaging to evaluate the effectiveness of stem cell therapy in patients with coronary heart disease. The study found that stem cells improved damaged heart function, surpassing improvements from increased blood flow to the affected area.
A study using PET scans found that cognitive behavioral therapy alters brain chemistry in patients with bulimia nervosa, particularly in regions related to feeding and reward. The results suggest a relationship between opioid receptors and bulimic behavior, potentially informing more effective treatment strategies.
A recent study suggests that Cyr61 gene therapy may be effective in treating severe myocardial ischemic disease by inducing the growth of new blood vessels. The research found potent stimulation of myocardial angiogenesis, a novel gene therapeutic approach, using Cyr61 in a porcine model of chronic myocardial ischemia.
A German-developed expert system enhances the diagnostic accuracy of Alzheimer's disease using FDG PET scans. The system, which was tested in 150 cases, helps inexperienced physicians diagnose Alzheimer's and differentiate it from other dementia disorders.
Acute respiratory distress syndrome (ARDS) can be predicted using PET scans in trauma patients, allowing for early treatment with aggressive immune modulation therapy. This method has the potential to reduce mortality rates and improve patient outcomes.
The Gamma Medica imaging system enables researchers to use PET only, CT only, or a combination of modalities, allowing for flexibility and efficiency in research objectives. This tri-modality system is expected to speed up the development of life-saving drugs by enabling faster and more efficient work.
Researchers have made advances in nuclear medicine, providing alternatives to traditional chemotherapy treatment for non-Hodgkin's lymphoma patients. The new treatments showed improved response rates and durations, exceeding those following chemotherapy, and offer a personalized dose option.
Researchers from Munich discovered that sequential FDG-PET can identify responding tumors after just one cycle of chemotherapy, allowing for earlier assessment of treatment efficacy. This could lead to more accurate individualized treatment and improved patient outcomes.
The Cleveland Clinic Health System has implemented a mobile PET/CT unit, providing on-site cancer diagnosis to patients in need. The cooperative efforts of all involved hospitals have made the service a successful operation.
A recent study found that caffeine intake can significantly affect myocardial uptake on PET/CT scans, making it harder to detect lesions near the heart. Researchers recommend avoiding caffeine and exercise before imaging to ensure a clear view of the body.
Researchers have successfully applied a novel PET/CT technique to characterize the effects of a gene therapy intervention in animal models, demonstrating its potential for improving cardiac health. The study showed that successful transfer of a VEGF gene resulted in increased tissue perfusion without impairing cardiac function.
David M. Goldenberg, a pioneer in radiolabeled antibodies, has received the Society of Nuclear Medicine's 2005 Paul C. Aebersold Award. He has developed antibodies for various cancer types and therapies, making significant contributions to nuclear medicine.
Larson, a leading expert in targeted radiotherapy and molecular imaging, has made significant contributions to the advancement of positron emission tomography (PET) as a clinical tool for oncology. His research has led to novel findings in cancer understanding and treatment.
David James Brooks, a pioneer in applying PET to movement disorders, received the Kuhl-Lassen Award for his groundbreaking research on Parkinson's and related disorders. His work has improved understanding of disease progression, diagnosis, and therapeutics.
Researchers used PET/CT scans to evaluate nearly 2,000 cancer patients and detected unexpected additional malignancies. These newly identified lesions are often of early stage and have a better likelihood of being cured if treated promptly and aggressively.
Small animal imaging allows for repeated, non-invasive studies on the same living subject, providing crucial information on disease progression and treatment outcomes. This technology enables researchers to gain insights into human biology and disease, leading to improved diagnosis and development of innovative drugs.
Researchers used PET/CT to diagnose foot infections in diabetics by detecting glucose uptake with labeled radiotracer 18F-FDG. This approach facilitated better localization of infection and structural changes in bone and soft tissues, showing promise for more accurate diagnoses.
The study used combined PET and MRI to track cocaine pharmacokinetics in pregnant nonhuman primates. The results showed that cocaine accumulated at the highest levels in the liver, and to a lesser extent in the brain, suggesting a unique anatomy of fetal circulation.
Researchers have developed a new fluorine-18 labeled imaging agent, nifrolidine, which binds to a receptor involved in cognition and learning. This receptor is also linked to nicotine addiction and lung cancer, making it a potential target for early Alzheimer's disease diagnosis and treatment.
The Journal of Nuclear Medicine Supplement offers a comprehensive overview of radionuclide therapy, including its applications in thyroid cancer, lymphoma, and other diseases. The supplement highlights the growing importance of nuclear medicine in patient care and provides insight into emerging trends and technologies.
The study found that PET/CT imaging was effective in detecting new malignancy and precisely localizing disease extent in patients with suspected occult recurrent cancer. The imaging modality provided valuable information for treatment planning, potentially avoiding further invasive procedures.
A study using combined positron emission tomography and computed tomography may help detect early abnormalities in the arterial wall, potentially useful for early disease detection, prevention, and prognosis. Nuclear medicine could provide valuable information on plaque composition.
A study by Johannes Schwarz and colleagues tracked molecular changes in brains of Parkinson's patients over 7.5 years using SPECT to measure dopamine transporter binding, revealing a single exponential decline rather than linear loss. This advancement enables the development of individualized treatment for advanced Parkinson's patients.
Researchers in The Netherlands and Belgium developed a new technique that uses genetically engineered rhTSH to stimulate thyroid cancer cells to absorb radioactive iodine, avoiding hypothyroidism and increasing safety. This approach may allow higher doses of radioiodine to be used when needed, improving treatment efficacy.